Takeda Pharmaceutical has reported positive results from the Phase III ALTA-1L clinical trial of Alunbrig (brigatinib) in patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).
Alunbrig is a selective tyrosine kinase inhibitor (TKI) of the ALK fusion protein in NSCLC. The ALTA-1L trial assessed the drug in 275 adult patients who did not receive previous treatment with an ALK inhibitor.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In newly diagnosed participants whose cancer had spread to the brain at baseline, risk of disease progression or death decreased by 76% with Takeda’s drug compared to crizotinib.
The drug led to a 57% reduction in overall patient population.
At the data cut-off date of 28 June 2019, a second interim analysis showed a 51% decrease in the risk of disease progression or death on the primary endpoint of progression-free survival (PFS).
Long-term analysis involving a follow-up period of two years found a positive response with Alunbrig in newly diagnosed patients with or without brain metastases at baseline.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe drug demonstrated superior efficacy over crizotinib in patients with baseline brain metastases.
Takeda Oncology Therapeutic Area Unit head Phil Rowlands said: “We are proud of the progress made thus far, including these updated results from the ALTA-1L trial, which show that Alunbrig delayed disease progression by more than two years and significantly reduced the risk of disease progression in patients with baseline brain metastasis.
“We look forward to submitting these data to regulatory authorities around the globe with the goal of making Alunbrig available to ALK+ NSCLC patients worldwide.”
Earlier this month, the company reported encouraging data from the ongoing Phase III TIDES study of its dengue vaccine candidate, TAK-003.
In a recent announcement, Takeda said that the vaccine’s efficacy was 73.3% at 18 months. The company noted that additional data is required to fully understand the profile of TAK-003.
